The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer
Open accessAbstract
Peritoneal dissemination in gastric cancer is a common fatal clinical condition with few effective therapies available. We studied the therapeutic effect of a tumor‐targeting drug delivery system that uses cisplatin‐encapsulated and Tf‐conjugated PEG liposomes (Tf‐PEG liposomes) in nude mice with peritoneal dissemination of human gastric cancer cells. Small unilamellar Tf‐PEG, PEG or DSPC/CH liposomes (bare liposomes) encapsulating cisplatin were prepared by reverse‐phase evaporation followed by extrusion. Electron microscopic studies revealed that Tf‐PEG liposomes were internalized into tumor cells by receptor‐mediated endocytosis. To examine the biodistribution of each liposome and cisplatin level, nude mice were inoculated i.p. with 10 7 MKN45P human gastric tumor cells. On the fourth day after tumor inoculation, 3 H‐CHE‐labeled and cisplatin‐encapsulated Tf‐PEG, PEG or bare liposome were inoculated i.p. The Tf‐PEG liposome–administered group maintained high liposome and cisplatin levels in ascites and showed a prolonged residence time in the peripheral circulation. Uptake of Tf‐PEG liposomes into the liver and spleen was significantly lower than that of bare liposomes. Uptake of Tf‐PEG liposomes in disseminated tumor cells of ascites and the greater omentum was significantly higher than that of PEG or bare liposomes and a significant increase in cisplatin levels was observed in these tumor cells. Mice receiving Tf‐PEG liposomes 1 and 4 days after the day of tumor inoculation showed significantly higher survival rates compared with those receiving PEG liposomes without Tf, bare liposomes or free cisplatin solution. These results suggest that cisplatin‐encapsulated Tf‐PEG liposomes may be useful as a new intracellular targeting carrier for treatment of gastric cancer with peritoneal dissemination. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transferrin and transferrin receptors in carcinoma of the breast
Page Faulk, W., Hsi, B.-L., & Stevens, P. J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90440-7 · Cited by 280
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Canton, I., & Battaglia, G. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15309b · Cited by 936
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Targeted pharmaceutical nanocarriers for cancer therapy and imaging
Torchilin, V. P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902015 · Cited by 762
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Self-assembled hyaluronic acid nanoparticles for active tumor targeting
Choi, K. Y., Chung, H., Min, K. H., Yoon, H. Y., Kim, K., Park, J. H., Kwon, I. C., & Jeong, S. Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.030 · Cited by 578
Ohshima, K., Inoue, K., Fujiwara, A., Hatakeyama, K., Kanto, K., Watanabe, Y., Muramatsu, K., Fukuda, Y., Ogura, S.-I., Yamaguchi, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013247 · Cited by 577
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Ligand-targeted liposome design: challenges and fundamental considerations
Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.09.007 · Cited by 542
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Polymeric nanoparticles for targeted treatment in oncology: current insights
Joshi, M. D., Patravale, V., & Prabhu, R. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s56932 · Cited by 438
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.031 · Cited by 332
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Sahoo, S. K., Ma, W., & Labhasetwar, V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327
Liposomes for Tumor Targeted Therapy: A Review
Wang, S., Chen, Y., Guo, J., & Huang, Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032643 · Cited by 315
pH-Sensitive liposomes-principle and application in cancer therapy
Karanth, H., & Murthy, R. S. R. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.4.0001 · Cited by 294
Molecular imaging with nanoparticles: giant roles for dwarf actors
Debbage, P., & Jaschke, W. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0511-y · Cited by 264
Singh (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s8030 · Cited by 253
Nanoparticle formulations of cisplatin for cancer therapy
Duan, X., He, C., Kron, S. J., & Lin, W. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1390 · Cited by 216
Binding and interstitial penetration of liposomes within avascular tumor spheroids
Kostarelos, K., Emfietzoglou, D., Papakostas, A., Yang, W., Ballangrud, Å., & Sgouros, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.20457 · Cited by 127
Metadata
- Authors
- Iinuma, H., Maruyama, K., Okinaga, K., Sasaki, K., Sekine, T., Ishida, O., Ogiwara, N., Johkura, K., & Yonemura, Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-03-27
- Volume
- 99
- Issue
- 1
- Pages
- 130-137
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1970038366
- Cited by
- 216
- References
- 1
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.